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The Nifedipine Gastro-lntestinal Therapeutic System (GITS) Cir-
cadian Anti-ischemla Program (N-CAP) was designed to test the
effect of nifedipine GITS as monmherapy , or in combination with
a beta
•a
drenergic blocking agent on the circadian pattern of
angina and silent ischemia in patients with chronic stable angina .
At 118
sites
in the United States, 1,174 osuents were screened for
entry into this study . To he eligible for participation patients were
required to have at least two episodes of angina a week and at least
two episodes of myocardial Isebemla during 48-h ambulatory
electrocardiographic (ECG) monitoring during the baseline pta-
ceho period . A total of 207 patients completed all phoses of the
study. beta-blockers were continued in those patients already
receiving them .
In this 7- to 10-week single-blind placebo withdrawal study, a
1-week placebo run-in was followed by up to 5 weeks of single-
blind titration with nifedipine GffS, a 4-week efficacy phase with
an established dose and a final single-blind 2-week placebo with.
drawal ;eriod. Ambulatory ECG monitoring was performed at
the end of each placebo phase and at the end of the el icacy phase
with a digital monitoring device that was validated in a pilot study .
Overall, nifediplue GITS signncantly reduced the weekly
In patients with chronic stable angina, the incidence of
myocardial ischemia is underestimated by symptoms (1,2) .
Monitoring of the ST segment on an ambulatory electrocar-
diogram (ECG) can be used to obtain an objective measure-
ment of myocardial ischemia during normal daily activities
(3,4) . Detection of myocardial ischemia in this way after
relief of angina has been related to increased cardiovascular
morbidity (5) and possibly mortality (6) .
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number of anginal episodes from 5.7 to 1 .8 (p = 0.1101) and the
number of isebemic events from 7 .3 to 4 (p - 0 .0801) reported
during the 48-h monitoring periods, vilth a significant increase in
both during the placebo withdrawal period
. The baseline circa•
than pattern of Ischemia showed an early morning peak and a
secondary peak in the afternoon . Nifedipine GITS significantly
reduced ischemia during the 48-h period when administered as
monotherapy or in combination with a beta-blocker. Patients were
also randomized to receive nifedipine GITS in either a morning or
an evening dose. The two
regimens resulted in equal anti-hschemic
benefit . The primary side effect of nifedipine GITS was edema,
which was dose related.
In summary, nifedipine GITS reduced the number of anginal
and ischemic episodes
when given alone or in combination
with a
beta-blocker. Nifedipine GITS had a sustained effecth a single
daily dose was effective over 24 h regardless of whether it was
administered in the morning or evening . This study also suggests
that combination therapy
with nifedipine GITS and a beta•blocker
Is especially efficacious in reducing ischemia.
(3 Am Can Cardiel 1992;19 :1380-9)
Both painful and painless ischemic episodes have been
shown to exhibit a circadian
pattern, with a peak incidence
of ischemia in the early morning hours (7) that resemble- the
circadian pattern observed for nonfatal myocardial infarc-
tion (8) and sudden cardiac death (9) . It is thus appropriate to
design and
test therapeutic regimens that will treat this
pattern of ischemia and, in particular, cover the early
morning period when ischemia is most common and the risk
of adverse cordiovoscuior events is greatest .
Both beta-adrenergic blocking agents and calcium chan-
nel blockers are
effective in reducing ischemia when used
alone or in combination (10,11). Oncedaily administration of
atenolol and metoprolol
have been reported (12,13) to reduce
the incidence of ischemia over 24 h . However, calcium chan-
nel blockers with a short plasma half-life, such as nifedipine,
have proved disappointing in this regard (13). Their ineffec-
tiveness may be related
to the rapid absorption of drug and
resulting high peak plasma levels
with consequent side
effects and unpredictable dose response in individual
pa-
tients (14) . This pharmacokinetic-pharmacodynamic profile
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may be accentuated by the multiple daily dosing required for
these agents. Nifedipine Gastro-Intestinal Therapeutic Sys-
tem (GITS) is a once-a-day formulation th-rt uses an osmotic
push-pull mechanism to provide an essentially constant,
controlled rate of drug release, which results ~n stable
plasma levels over 24 h (15,16), The Nifedipine GITS Circa-
dian Anti-ischemia Program (N- CAP) was designed to test
the effect of nifedipine GITS- either as morotherapy or in
combination with background beta-blocker therapy, on the
circadian pattern of transient myocardial ischemia in pa-
tients with chronic stable angina
.
Methods
Patient selection. The study group consisted of patients
who met the following entry criteria : men and women 35 to
80 years of age, with women participants nut of childbearing
potential
; a diagnosis of chronic stable angina pectoris with
at least two episodes of symptomatic myocardial ischemia
each week and at least two episodes of myocardial ischemia
on 48-h ambulatory ECG monitoring during the baseline
placebo period, and a history of stable angina pectoris
related to exertion or emotion and relieved by nitroglycerin.
The pattern of angina had to be stable :or > I Four..'h, with no
recent history of unstable angina or myocardial infarction .
Documentation of coronary artery disease required or
least one of the following: 1) coronary angiogmm demon-
strating 70% diameter narrowing of at least one major
coronary artery; 2) acute myocardial infarction at least I
month before screening, documented by a typical history,
evolving ECG changes or diagnostic serum enzyme changes
(two of three criteria required) ; 3) positive findings on an
exercise treadmill test with ischcmic ECG changes ; and 4) a
history of coronary artery bypass graft surgery or percuta-
neous transluminal coronary angioplasty . Patients taking no
other cardiac medications were eligible, as were patients
currently taking a beta-blocker. However, patients being
treated with a calcium channel blocker or long-acting ni-
trates had to be withdrawn from those medications before
screening .
Among exclusion criteria were clinically significant con-
gestive heart failure, the presence of left ventricular hyper-
trophy by ECG criteria, iniraventricular conduction defect,
digitalis use, baseline ST segment depression >0.5 mm or
any other condition in which interpretation of the ST seg-
ment would be difficult . Other exclusion criteria were
chronic or acute diarrhea, chronic use of laxatives, use of
other inve9tigaiional drugs within I month of the study and a
previously demonstrated intolerance to nifedipine. All pa-
tients gave informed consent in a manner approved by the
individual testing site's Institutional Review Board . Screen-
ing took place at 118 sites between August 1988 and June
1990 .
Study design (Fig. 1).
This 7- to 12-week single-blind
placebo withdrawal study consisted of an initial I-week
placebo wash-in (phase 1), up to 5 weeks of single-blind
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Figure 1 . Study design . GITS = Gastro-Intestinal Therapeutic
System
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ntitmtio  of nifedipine GITS (phase II), a 4-week efficacy
phase with maintenance of the previously established dose
of nifedipine GITS determined during the
titration
phase
(phase 111) and a final 2-week single-blind placebo with-
drawal period (phase IV) . At the beginning of phase 1, a
complete medical history and physical examination were
performed and patients were given a 60-mg nifedipine GITS
placebo tablet daily in a single-blind fashion throughout the
I-week placebo baseline period
. At the end of phase l, a 48-h
continuous ambulatory ECG was obtained . During all study
phases, patients were instructed to record in a diary all
episodes of angina, sublingual nitroglycerin tablet consump-
tion and side effects . In addition, an hourly activity log was
kept by the patients during the 48-h continuous ambulatory
ECG monitoring periods . Eligible patients were than ran-
domized to receive nifedipine G1TS according to either a
morning or an evening dosing schedule during phase Il .
Single-blind titration ofn fdip in-e GJJT5
,resp ee
f rued
in
the following manner : patients received a 30-mg nifedipine
GITS tablet orally and were contacted the next day for a
report of symptoms or side effects . If the initial dose was
tolerated, the patient continued on that therapy for I week .
At the start of the 2nd titration week and for all subsequent
titration weeks, patients were again contacted for a report of
symptoms and side effects. If the patient remained sympto-
matic but did not experience significant side effects, the
dosage was increased by an additional 30 mglday during the
following week . Patients were titrated to one dose level
above that at which symptomatic angina was abolished or to
a maximal dosage of 180 mg/day of nifedipine GITS. During
phase III, the medication was maintained at a stable dose as
determined during she titration phase. At the end of phase
III, patients returned for a repeat 48-h continuous ambula-
tory ECG . After completion of the 4-week elicacy period,
active nifedipine GITS study medication was discontinued
and replaced with single-blind nifedipine GITS placebo
tablets. During the phase IV washout period, the number of
placebo tablets equaled that of the active nifedipine GITS
tablets administered during phase Ill- During the 2-week
final placebo washout period, patients completed the angina
and nitroglycerin usage diary and activity log and underwent
a third 48-h continuous ambulatory ECG recording at the
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end of the period . Other than communication of initial
ambulatory ECG eligibility data, the clinicians and the
individual testing sites were not informed of subsequent
ambulatory ECG results .
Medication compliance was assessed by using standard
pill count techniques during, JI clinic visits
. Other calcium
channel blockers and long-acting nitrates were discontinued
before the initial screening and throughout the study period .
Beta-blocker therapy was maintained at a stable dosage
throughout the study for patients who were taking a beta-
blocker at study entry. In addition, patients were given
sublingual nitroglycerin for symptomatic episodes of angina
pectoris.
Continuous ambulatory ECG monitoring . Continuous,
two-channel, 48-h ambulatory ECG monitoring was per-
formed at the end of the initial placebo wash-in (phase 1), at
the end of the active drug efficacy phase (phase III) and after
the final placebo a ushout period (phase IV) . Leads II and V s
were generally used throughout the study as the default
leads . Lead selection was modified for individual patients if
ST segment depression at rest was >0 .5 mm, if R wave
amplitude was inadequate at the default leads or if ischemic
ECG changes in alternate leads were detected on prior
exercise testing.
The ambulatory ECG monitoring and analysis system
consisted of a digital monitoring device. (Monitor One TC
350, gmed) with tcaastelephonic capabilities for direct input
of ail original ECG data into a remote central data base. The
device is a solid state, ambulatory ECG monitor that uses a
clinically validated algorithm for detection and analysis of
ST segment amplitude based on criteria consistent with the
guidelines put forth by the National Institutes of Health
Consensus Conference (17-22). The system performs on-line
digital analysis of the ST segment, provides an ST segment
trend with I-min resolution and prints and stores in memory
all discrete episodes of ST deviation that meet amplitude and
duration criteria programmed by the user for physician
review . Each episode of ST deviation is annotated with its
duration, heart rate at onset of the episode and time of
maximal ST deviation . If pain occurred dining the ST
episode and the patient pressed the event brton, the re-
corded event was automatically annotated to indicate the
presence of pain. The criteria for detection of abnormal ST
segment depression used in this study were ?60 s of hori-
zontal or downsloping ST segmem depression occurring 60
to 80 ms after the J point and lasting >_60 s. The duration of
each episode was defined as the time interval between the
initial 1 mm of ST segment depression at the beginning of the
episode to the time when the ST segment depression became
<I mm for >_60 s at the end of the episode . In addition, the
system documented the minimal, mean and maximal heart
rate for each 15-min period during the 48 h of monitoring .
The ST segment elevations were infrequent and thus were
not included in analysis of ST segment change . Despite
attempts to prospectively exclude patients before phase I by
verifying initial ECG strips for acceptable ECG criteria,
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patients were subsequently considered ineligible for study
inclusion if baseline ST segment depressions were >0.5 mm
for >24 h of the 48 h of ambulatory ECG monitoring period .
Real time quality control, data transmission and analysis .
At the time of preparing each patient for ECG monitoring
during phases 1, 111 and IV, a sample two-lead ECG was
transferred electronically by modem to the Central Ambula-
tory ECG Monitoring and Archival Station (Clark, NJ),
where it was immediately evaluated for signal adequacy . If
the signal met the baseline ST segment depression
(s0
.5 mm) and R wave (>7 mm amplitude) criteria and was
otherwise technically suitable, the lead positions were con-
firmed and recording of the 48-h continuous ambulatory
ECG commenced, If artifact or
unacceptable
ECG criteria
were detected, the investigator was immediately notified by
telephone and the leads were reapplied and retested until a
technically suitable two-channel recording could be ob-
tained. For phase III and IV ambulatory ECG recordings,
the ECG signals were additionally compared with the pa-
tient's phase I ECG samples to ensure that each patient was
subsequently being monitored in the same lead configura-
tions. This quality control measure ensured that valid com-
parative ECG data were collected during each monitoring
phase .
After completion of the first and all subsequent 48-h
monitoring sessions, the monitoring device was downloaded
at a modem station, and the digital ECG data were electron
.
ically transferred by modem to the Central Ambulatory
Monitoring and Archival Station
. The ambulatory ECG
digital data were stored in replicate copies on a central
computer before being forwarded to the Biostatistics Depart-
ment at the Study Coordinating Center (New York, NY) . A
copy of the entire report was then printed and transmitted by
facsimile to the Ambulatory ECG Review Center (Balti-
more, MD) for physician review and confirmation of ambu-
latory ECG eligibility criteria. With use of this automated
system of electronic transmission, data were reviewed
within 24 h at the Ambulatory ECG Review Center, and
determination of eligibility (two or more episodes of ST
segment depression during the 48 h) by the physician ambu-
latory ECU overreader was communicated immediately by
facsimile to the Study Coordinating Center
.
In that manner, patients who did not meet entry criteria
or those with technical artifacts or lead dislodgment were
immediately identified and were not entered into the study
.
Consistent criteria for entry were employed to determine
eligibility for study inclusion, and patients without confirmed
episodes of ST segment depression were not entered into the
study . After ambulatory ECG eligibility was determined, the
Study Coordinating Center notified the investigational study
site of the result
. Subsequent 48-h ambulatory ECG data
were transmitted by using the same modem system to the
Central Ambulatory Monitoring and Archival Station, where
paper printouts were produced and sent for final review to
the Ambulatory ECG Review Center . Each episode of ST
segment depression identified by the computer analysis was
JACC Vol. 19 . No. 7
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visually verified, and artifacts and other technical problems
were edited by a physician overreader . The review of the
ambulatory ECG recordings was conducted in large batches
in a manner such that the reviewer was unaware of the
clinical status of the patient or treatment phase . All reports
and all ST segment episodes were reviewed by one physician
overreader to provide consistency throughout the overa!]
study
. The results of the overreading were transmitted in
batches to the Study Coordinating Center- where editing of
the data base was performed . All ambulatory ECG reviews
for study eligibility that resulted in disqualification or exclu-
sion of the patient from the study were documented, includ-
ing the reason for exclusion .
After the final ambulatory ECG reports were reviewed, a
blinded repeat review of all reports in which any editing was
done was conducted to determine the intraobserver variabil-
ity of the editing . Overall, a concordance ratio >90% was
noted in the blinded repeat review of all editing involving 60
patients.
Prestudy validation of the algorithm and system. The
ambulatory ECG monitoring system (Monitor One TC 350)
has been validated (19-21,23,24) to ensure the accuracy of
its automatic detection and recording of episodes of ST
deviation as assessed by comparison with human overread-
ing of both direct writing and computer
.assisted tape-based
ECG systems . However, before the study, another valida-
tion study was performed by members of the study Steering
Committee to verify the reported accuracy it . the published
studies (19-21,23,24). The ambulatory ECG solid state mon-
itor and an amplitude-modulated analog tape system (Del
Mar Avionics) were compared in a group of 32 patients with
established coronary artery disease and technically suitable
ECG signals. Both systems were worn simultaneously for
24 h, and the recordings were analyzed separately in a
blinded manner for the occurrence of episodes of m I mm ST
segment depression lasting for a60 s . Contiguous leads with
separate skin patches were used, and the wires were placed
as precisely as possible at the same skin location . Because of
the minor calibration variations noted in the analog system
calibration signals ('-5% to 10%) and the slight differences in
amplitude attributable to side by side electrode placements,
the output from each system was considered correlated
when one system recorded Pat ST segment change al mm
and the other system recorded an ST segment change of 1
0 .2 mm in the same lead at the same time . With use of these
criteria, a 92% concordance was found between the detec-
tion of episodes of ST deviation by the Monitor One system
and the consensus reading of the tape-based recordings by
two investigators . Thus, the accuracy of the ambulatory
ECG system in its automated mode was deemed acceptable
for use in the full study .
Statistiglanayses . Descriptive statistics, including mean
values, standard deviations and frequency distributions,
were provided for baseline demographic and disease char-
acteristics . The changes from baseline and between treat-
ment phases for the number of episodes of angina and the
1383
number of nitroglycerin tablets taken and standardized per
week were analyzed by using paired r tests for the overall
patient grcup and within the subgroups . The ischemic event
data obtained during ambulatory ECG monitoring were
analyzed after employing a square root transformation for
both the number and the duration of events
. The overall
chaagcs beruee , treatment phases wer. evaluated by using
paired t tests. Response within individual subjects was
defined, and a value oft . 0 or - I was assigned to correspond
to improvement, no change or worsening, respectively_ A
signed rank test was used to determine whether the median
differed from 0
. The diurnal analysis consisted of repeated
measurement of analycs of variance (ANOVA) for the data
in 3-h intervals to test statistical significance of treatment
differences, diurnal effects and interactions . The significance
of the diurnal time effect was also evaluated separately at
baseline and during nifedipine GITS treatment visits. Re-
peated measures of analysis of variance were performed,
including ambulatory electrocardiography, both at baseline
and after nifedipinc GITS treatment to test tit , diurnal time
effect, treatment effect and their interaction. The same
model was used in the analysis of nifedipinc GITS and
placebo washout phases to assess statistical significance. All
analyses were conducted with SAS programs. Statistical
tests were performed by using two-tailed teats, and signifi-
cance was declared at the alpha = 0.05 lone! . Date are
presented as mean values ± SEM.
Results
Patient data. A total of 1,174 patients with chronic stable
angina were screened for the study . Of these, 820 patients
were ineligible and 354 received the study drug. The reasons
for patients' not entering or withdrawing from the study are
presented in Figure 2
. A wt a, ~i' i3 i paiii~ as were withdrawn
from the study mainly because of violations of protocol or
side effects . Of the 7 .`3 who completed the drug phase, 14
were withdrawn p.'taarily because of side effects . Of the
remaining 209 patients, I never received active study drug
and another did not have evaluable ambulatory ECG data .
Thus, evs'aable data were available in 207 patients .
Patient profile du.a fl, on the 257 path-nts are shown ir.
Table l . The average age of the 165 men and 42 women was
63 years . The average duration of angina was 5.4 years.
Approximate'y 75% of the participants had annuity history
of heart disease, 17% were smokers, 38% had had a previous
myocardial infarction and many had undergone percutane-
ous transluminal coronary angioplasty or bypass surgery .
The majority of patients (79%) had a ?70% stenosis in one or
more vessels .
Efficacy data: weekly ang+aal attacks and nitroglycerin Ice .
Figure 3 shows the average weekly rate of anginal episodes
and the number of nitroglycerin tablets/week used in the
three treatment nhases . Data are shown for all patients (n =
207), those who received only nifedipine GITS (monother-
apy) (n = 92) and those who were given combination therapy
1384
	
PARMLEY ET AL .
NIFEDIPINE OI I S AND CIRCADIAN PATTERNS OF MYOCARDIAL ISCHEMIA
1820 reel glbleI
[131 disoontinaed
•
77 prolocel violations
• 3eslaeaneale
nethe, 14unralsled
Illns,d pecilied)
51
es
ack of ellkacy"
a aamlnlslrauve
11174 patients screened
354' received study drug
223' completed drug
treatment phase
	r
209' completed drug
withdrawal phase
1207 had
ovaluable Hotter data
: . One pallentcomplellnglhlsphasedidnotrevolveactivedrug
As fudged by invesligator
with a beta-blocker and nifedipine GITS (n = It5). Com-
pared with placebo, treatment with nifedipine GITS
resulted
in a significant decrease in weekly episodes of angina (mean
SEM 5 .7 ± 0.43 to 1 .8 ± 0 .22, respectively) and nitro-
glycerin consumption (4 .1 ± 0.4 to 1 .6 ± 0 .28 tablets,
respecr' rely) . Withdrawal of nifedipine GITS therapy re-
sulted, , a significant increase in both episodes of angina (3 .9
± 0 .4•y and nitroglycerin use
(3 .3
± 0 .47 tablets)
. A similar
decrease in weekly episodes of angina and nitroglycerin use
was seen whether nifedipine GITS was given alone (5
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Figure 2 . Patient flow diagram .
0.54 to 1 .9 ± 0 .37 episodes of angina; 4.5 ± 0 .6 to 2 .1 ± 0 .54
tablets of nitroglycerin) or in combination with a beta-
blocker
(5 .9 ± 0.64 to 1 .6 ± 0.27 episodes of angina; 3.8
0.55 It 1
.3 ± 0.26) tablets of nitroglycerin . Episodes
of
angina and nitroglycerin use increased significantly when
active therapy was withdrawn in the monotherapy (3 .2 ±
0.54 episodes of angina; 3 .0 ± 0 .65 tablets of nitroglycerin,
respectively) and combination (4.4 ± 0.67; 3 .6 ± 0.68 tablets
of nitroglycerin, respectively) groups .
Ischemic events on ambulatory ECG monitoring. The
effect of nifedipine GITS on the number and total duration of
Figure 3 . A, Weekly rate of angina] episodes during the placebo,
nifedipine GITS and withdrawal phases in all patients (chcks) and in
patients who received monothempy (diamonds) or combination
therapy (Triangles). Statistical comparisons: p = 0 .0001 (sen), pla-
cebo versus nifedipine GITS, all groups
; p = 0.001 (**), nifedipine
GITS versus withdrawal, all groups. B, Weekly nitroglycein (NTG)
consumption during each study phase . Statistical comparisons: p =
0 .0001 ('**), placebo versus nifedipine GITS, a0 groups
; p = 0.0001
nifedipine GITS versus withdrawal, all patients and patients
who rece' •ed combination therapy or monotherapy p = 0 .003 (*) .
Values are mean values ± SE .
Mean no.
angina aftacksAak
Mean no.
of NTG tablelslwk
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Table f . Demographics for 207 Evaluable Patients
(yr)
62 .6 s B.4-
Gender
Mate 165
Female 42
Race
White
174
Black 21
Other 12
Angina duration (ye) 5.4 ±
5 .8-
Funnily histsrt of heart disease
Yes
151
No 41
Uncertain 14
Cigarette smoker
Yes
36
No 171
10s:c y of myocodial infnrclioe
yes 79
No 127
Previous coronary angioplasty
yes 56
Na
Previous cerdiae surgery
Yes
Ill
56
No 151
Positive ones ice treadmill lest
yes 173
No
6
taadequate
t)
'Mean value ± SD .
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Figure 4. A, The mean number of ST segment events on ambulatory
electrocardiographic monitoring during the placebo. nifedipine
GITS (N•G ITS) and withdrawal phases in all patients (decks) and in
patients who received monotherapy (dtamands) or combination
therapy (triangles) . Statistical comparisons
: p -
0.0001 (*"*), pla-
ceho versus nifedipine GITS, all groups ; p = 0 .01 N
. nifedipine
GITS versus withdrawal, all patients and p -= 0.003 (°'), combina-
tion group. B, Mean duration of ST segment events during each
study phase . Statistical comparisons : p = 0.0001 ("`), placebo
versus nifedipine GITS, all groups. Values are mean values ± SE .
ischemic events during the 48-h ambulatory ECG monitoring
period is shown in Figure 4. Compared with the initial
placebo ton-in phase, treatment with nifedipine GITS signif-
icantly
reduced the number of ischemic events from 7 .23 m
0.6 to 4 .0 t 0 .4, as well as the duration of events from 69 .57
± 7,3 to 47.6 t 8.0 min. When nifedipine GITS therapy was
withdrawn, the number of ischemic events increased signif-
icantly to 5 .23 *- 0.6 with no change in event duration .
Similar effects were observed in patients with or without
baseline beta-blocker therapy
.
In patients who received nifedipine GITS as monother-
apy, there were significant decreases in the total number of
ischemic events (7 .6 ± 0.9 to 4 .6 ± 0.7) and the duration of
events (83 .2 -s 13 .1 to 52.9 * 9.4 min); no significant effect
was observed when therapy was withdrawn. Addition of
nifedipine GITS to background beta
•blocker therapy signif-
icantly reduced the number of ischemic events (7 .0
--
0.8 to
3 .5 a 0
.5),
whereas withdrawal of nifedipine GITS was
associated with a significant increase in the number of
ischemic events to 5 .6 ± 0.8. A similar treatment effect on
the duration of events was observed
; nifedipine GITS signif-
icant y decreased the duration from 58 .6 ± 7.8 to 43 .4 ±
12 .2 min, and the duration increased significantly to 52.6 t
10,7 mitt when therapy was withdrawn,
Circedia variation. The circadian variation of ischemic
events detected by 48-h ambulatory ECG monitoring and the
effect of treatment is illustrated in Figure 5. The number of
events for each 3-h block of time throughout the day is
a 3 a 9 12 is
15
M--therapy
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b
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Figure 5. The circadianpattemofischemiceveatsassessedby40-h
ambulatory electrocardiographic monitoring at the end of the pta-
echo (squares). nifedipine GfrS (dreks) and withdrawal (triangles)
phases. Values are the mean number of events per 3-h intervals.
°p values for nifedipine GITS versos placebo. fp values for nifedi-
pine GITS versus withdrawal
.
shown for all patients, for those who received nifedipine
GITS monotherapy and for those on combination beta-
blocker and nifedipine GITS therapy. In each panel, data are
shown for the placebo phase, the nifedipine GITS phase and
after withdrawal from active drug . During the baseline
placebo phase, two peaks of ischemia were evident, one in
the morning (6
:00 AM to 9:00 AM) and another it approxi.
mutely 6 M PM.
Ndedipine GITS significantly reduced isch-
emia throughout the day . The reduction in isehemia was
similar whether nifedipine GITS
was given alone or in
combination with a beta-Mocker.
The effect of dosing rime of n(fedipiee CUTS (morning vs.
evening) on the circadian variation of ischemic events is
shown in Figure 6 . Nifedipine GITS, whether given in the
morning or evening, effectively reduced the number of
ischemic events throughout the 24-h period. The circadian
variation of hew rate, an index of myocardial oxygen
demand, was also assessed during the 4&h ambulatory EM
monitoring period (Fig
. 7)
. Compared with the placebo
phase, heart rate increas_d an average of 1 .6 + 5.2 bentslmin
over the 48 h. This modest effect was similar for all time
intervals studied and for all patient groups.
Adverse
effects . Table 2 summarizes the side effect profile
reported during the placebo and nifedipine G1TS phases
.
Side effects that occurred with a a3% incidence are listed
together with the dose of nifedipine GITS at which they were
first reported, Only edema, which increased with increasing
dose, occurred with a greater frequency during treatment
with nifedipine GITS than with placebo . The incidence of
other side effects reported :with nifedipine GITS was similar
to that seen during placebo treatment. One patient died
1386
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Figure 6 . The effect of morning (AM) versus evening (PM) dosing on
the circadian pattern of ischemic events assessed by 48-h ambula-
tory electrocardiographic monitoring at the end of the placebo
(squares), nifedipine GITS (circles) and withdrawal (triangles)
phases. Values are the mean number of events pr :r 3-h intervals .
5 p values for nifedipine GUS versus placebo
. p values for nifedi-
pine GITS versus withdrawal .
suddenly during the placebo phase of the study, and three
patients had a myocardial infarction during the titration
phase . Of those three patients, two manifested a significant
number of ST segment events on ambulatory ECG monitor-
ing during the baseline placebo period . One patient had 122
episodes of ST segment depression and the other had 26
episodes of ST segment depression and 27 episodes of ST
segment elevation during the 48-h monitoring period .
Figure 7 . Variations in heart rate assessed by 48-h ambulatory
eloetrocardiographic monitoring at the end of the placebo (squares),
nifedipine GITS (circles) and withdrawal (triangles) phases . Values
are the mean number of events per 3-h intervals. tin values for
nifedipine GITS versus withdrawal .
Discussion
Previous studies on silent Ischemia. Numerous studies
(5,6) have indicated that silent myocardial ischemia docu-
mented by ambulatory ECG monitoring has prognostic sig-
nificance in patients with chronic stable angina . These
studies revealed that the presence of such ischemia was an
independent marker of morbid coronary events such as
myocardial infarction and sudden death (11,25)
. Studies
have indicated that beta-adrenergic blockirg agents (11,12)
and nitrates (11,26) exert a significant suppressant effect on
silent myocardial ischemia. Ja addition, ccia-adrenergic
blockers have markedly altered the circadian pattern of
ischemic episodes and their d,nation, porn: alarly with re-
gard to the increased occurrence of surges in ischemia in the
early morning hours (12,13). The effects of :,:alcium channel
blockers in this regard have been inconsistent and somewhat
variable (13,27)
. Although nifedif.inc given alone or in com-
bination with a beta-blocker has been reported (28,29) to
effect a significant reduction in episodes of silent myocardial
ischemia, Mulcahy et at . (I3) showed no effect of nifedipine
capsules on the morning increase in ischemia . It is possible
that the inconsistent effects of calcium channel blockers
reflect their pharmacokinetic properties and the resulting
variable plasma levels of drug with conventional intermittent
dosing strategies. The availability of the extended-release
(GITS) formulation of nifedipine permitted the evaluation of
the effects of such a formulation on the number of ischemic
episodes, their cumulative duration and their circadian
rhythmicity as documented on ambulatory ECG monitoring
in patients with coronary artery disease and chronic stable
angina .
Anti-ischemic effects of nifedipine GITS. In this study,
nifedipine GITS given once daily over a wide range of doses
exerted significant anti-ischemic effects in patients with
chronic stable angina . For example, the drug significantly
lowered the rate of anginal episodes and the number of
nitroglycerin tablets consumed each week while diminishing
the total number of ischemic episodes and their mean
duration quantified during 48-h ambulatory ECG monitoring.
There was a significant response to nifedipine GITS over the
entire spectrum of severity of ischemia during monotherapy
as well as during combination therapy with a beta-blocker .
Because the effect of monotherapy with nifedipine GITS was
significantly greater than that of placebo, the salutary effects
of the calcium channel blacker were not attributable to the
beta-blacker during the combination therapy.
In this study, withdrawal of nifedipine therapy was asso-
ciated with a significant increase in the number of weekly
anginal episodes and of nitroglycerin tablets required for
sympiom relief. Similarly, when nifedipine GITS was with-
drawn, the total number of ambulatory ischemic events
increased, although not to the original placebo baseline
value . The reason for this effect is not entirely clear .
Carryover of a persistent drug effect 2 weeks after cessation
of therapy is unlikely given the short half-life of nifedipine
m
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(16). One possible explanation may be related to the biology
underlying myocardial ischemia and its inherent variability
on repeat measurements using ambulatory ECG monitoring .
Because inclusion criteria for Inns study required the pres-
ence of both angina and ambulatory ischemia, investigators
enrolled patients whose level of disease may have been
particularly active, Over the course of the trial, subsequent
ambulatory monitoring was performed when the oisease may
have been less active-an example of regression toward the
mean . Overall. nifedipine G1TS therapy was well tolerated ;
the majority of side effects in patients were seen at titration
to doses >60 mg/day and were related to the vasodilator
effects of the drug .
Circadian rhythmicity of myocardial ischemia and nifedi-
pine GITS. Our data are of
particular
interest relative to the
effects of nifedipine GITS alone and in combination with a
beta-blocker on the circadian rhythmicity of heart rate and
ischemic episodes . Many cardiovascular disorders, includ-
ing myocardial infarction (8), sudden death (9) and stroke
(30),
exhibit a pattern of circadian rhythmicity similar to that
of heart rate, arterial pressure and catecholamine surges
(31), the major determinants of oxygen consumption . It is
therefore not surprising that ischemic episodes documented
on continuous ECG monitoring also exhibit a similar perio-
dicity, with very few episodes occurring between midnight
and 6
:00 AM, a marked morning peak and a second, more
variable peak later in the afternoon . This bimodal pattern
was confirmed in the current study during the placebo phase ;
the overall pattern was markedly attenuated during mono-
therapy with nifedipine GITS, and during the combination
therapy in which nifedipine G1TS was administered together
with a beta-blacker. However, the pattern of effect on the
two modes of therapy differed . This was particularly striking
in the case of the morning surge in myocardial ischemia,
which was nearly abolished by the combination therapy . As
previously reported (32), treatment was associated with a
slight (1 .6-beats/min) increase in mean heart rate when
averaged over the entire 48-h period .
Comparative and concomitant effects of nifedipine and a
beta-blocker . The data reported here are consistent with the
results of a smaller study by Nesto et al. (33). They found
Side effects are tabulated at the dose they were first reported . GITS = Gasuo'Imestinal Therapeutic System .
that when compared with placebo, nifedipine capsules given
four times a day (mean dosage 80 mg/day) significantly
reduced the number of spontaneous ischemic episodes and
almost completely abolished the morning surge in ischemia.
Similar findings were reported by Dargie et al . (28) and Coco
et al . (34) . Of particular interest are the data reported by
Cohn et al . (29) . In their study, nifedipine (40 mg/day)
reduced ischemic events on Hotter monitoring by 23%
overall and by 45% in patients with severe ischemia (that is,
more than three episodes or a cumulative duration ?60 min
over 48 h) despite anti-ischemic therapy with nitrates or a
beta-blocker. or both. In count-'ast, Frishman et al . (27) found
no benefit with nifedipine compared with placebo in reducing
ST segment depression when 90 mg/day of nifedipine was
administered in three divided doses . It is conceivable that
such a regimen may induce periodic dose-related increases
in heart rate that may negate the anti-ischemic action of the
calcium ar lagonist . In our study, a small nonsignificant
increase it heart rate was detected over the 24-h period .
Thus, the significant suppressant effects of the longer-acting
nifedipine GITS formulation on the morning surges in isch-
emia may be related in part to the lack of major increases in
heart rate. This possibility is supported by a strikingly lower
event rate during combination therapy, when the heart rate
in most patients may have been lower because of the
consistent use of a beta-blocker . These observations are
consistent with the greater anti-ischemic effects of a com-
bined regimen of propranolol and nifedipine than of individ-
ual agents given alone, as reported by Dargie et al . (28) in
patients with chronic stable angina and , hat by Gottlieb et al
.
(35) in those with unstable angina .
The apparent synergistic effect of nifedipine and a beta-
blacker in chronic stable angina may result from a beneficial
pharmacodynamic interaction between a calcium channel
blocker and a beta-blocker
. It is likely that any vasoconstric-
tor effect of a beta-blocker is nullified or reversed by a
:alcium channel blacker, whereas the reflex increases in
heart rate and contractility resulting from the potent vasodi-
lator action of calcium antagonists will
be neg.S :c lay a
beta-blocker.
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Table 2 . Percent Incidence of Side Effects During Placebo and Nifedipine UfIS 7 herapy
Nifedipis GITS
Placebo 30 mg m ma 9o mg 120 .g 150 mg 180 mg
In = 3531 In = 353) In = 297)
In = 238)
In = 167) In = 109)
(n
-
39)
Edema 0.3 3 .1 4.7 9 .2 8s 15.6 30 .8
Headache 4.0 4.8 27 -' .5 1 .8 6 .4 0
Dizziness 2 .0
2
5 LO 4.6 '-.4 2
.8 5.)
Con .tipation IA 0.8 in 2.1 3 .0 L8 5.1
Fatigue 0 .6 1 .4 1 .7 1 .3
1 .2 2 .8 0
Nausea L1 0 .6 0 0.8
.7
0.9
10.3
Chest pain 0.3 1 .4 1 .0 0 I .2 1 .8 0
Flushing 0.3 1 .1 0.3 0 .8 1 .2 0.9 it
Abdominal pain 0.3 0 .8
10
1 .3
0.6
0.9 2
.6
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Therapeutic implications and conclusions . This study is
limited by its single-blind fixed sequence design
. Further-
more, the stringent criteria for entry restricted its applica-
bility to a relatively small percent of the total number of
patients screened. Within these constraints, however, our
data show that nifedipine GITS reduces the rate of anginal
episodes and diminishes the number of ischemic episodes
and the; : cumulative duration detected on continuous ambu-
latory electrocardiography when given alone or in combina-
tion with a beta-blocker .
Nifedipine GITS had a sustained effect and markedly
attenuated the circadian pattern of ischemia, indicating that
a single daily dose provides a continuous anti-ischemic
effect
over 24 h . This effect was more striking when nifedipine
GITS was combined with a beta-blocker, the combination
producing a marked attenuation of the morning surge in
ischemia . Whether such a regimen might have a favorable
impact on the morbidity or mortality associated with silent
myocardial ischemia in patients with chronic stable angina
merits critical testing in controlled clinical trials .
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